Orchard Therapeutics plc (ORTX)

Jan 24, 2024 - ORTX was delisted (reason: acquired by Kyowa Kirin)
16.70
0.00 (0.00%)
Last trade price

Company Description

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany.

It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency.

The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations.

In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema.

The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co., Ltd..

Orchard Therapeutics plc
Orchard Therapeutics logo
Country United Kingdom
Founded 2015
IPO Date Oct 31, 2018
Industry Biotechnology
Sector Healthcare
Employees 166
CEO Dr. Hubert Baburaj Gaspar M.D., Ph.D.

Contact Details

Address:
245 Hammersmith Road, 3rd Floor
London, X0 W6 8PW
United Kingdom
Phone 011-44-0-203-3846700
Website orchard-tx.com

Stock Details

Ticker Symbol ORTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001748907
CUSIP Number 68570P101
ISIN Number US68570P2002
SIC Code 2836

Key Executives

Name Position
Dr. Bobby Gaspar M.D., Ph.D. Chief Executive Officer, Member of Scientific Advisory Board and Executive Director
Frank E. Thomas President and Chief Operating Officer
Dr. Nicoletta Loggia Ph.D. Chief Technical Officer
Dr. Fulvio Mavilio Ph.D. Chief Scientific Officer
Renee T. Leck Director of Investor Relations
Benjamin Navon Director of Corporate Communications
John Cerio Chief Human Resource Officer
Robin Kenselaar Senior Vice President and GM of EMEA Commercial Operations
Braden Parker Chief Commercial Officer
Dr. Leslie Meltzer Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Jan 24, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jan 24, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jan 24, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jan 24, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jan 24, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jan 24, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jan 24, 2024 POS AM Post-Effective amendments for registration statement
Jan 24, 2024 POS AM Post-Effective amendments for registration statement
Jan 24, 2024 8-K Current Report
Jan 24, 2024 25-NSE Filing